Sub-Community 于重元 [19/19] 劉柯俊 [85/98] 劉滄梧 [119/125] 劉界元(2003-2010) [3/3] 夏和雄(1996-2012) [26/31] 夏興國 [51/54] 姜乃榕 [82/94] 常慧如 [39/44] 張俊彥 [234/254] 張光裕 [69/79] 張憶壽 [104/107] 張文祥 [52/53] 張書銘 [89/91] 彭汪嘉康(1996-2007) [120/126] 施能耀 [37/43] 李家惠 [29/29] 李岳倫 [48/49] 林素芳 [32/32] 楊奕馨 [41/42] 江士昇 [88/90] 沈哲宏 [14/16] 洪文俊 [88/88] 莊雙恩 [82/91] 蔡坤志 [32/34] 蔡慧珍 [67/72] 蘇勇曄 [40/40] 蘇振良 [24/25] 郭靜娟 [71/76] 陳尚鴻 [45/48] 陳振陽 [72/72] 陳立宗 [444/511] 陳美霞(2002-2009) [1/1] 陳詩政 [2/2] 陳雅雯 [38/39] 黃智興 [55/55] 黃道揚 [26/26] 丁兆治(2000-2004) [5/5] 其他 [465/472] 劉敏(1996-2007) [60/62] 劉玫英(2004-2006) [2/2] 吳成文(1996-2008) [53/55] 曾思文(1997-2007) [4/4] 李冠德(1997-2004) [4/6] 林景太(1999-2007) [5/5] 楊文光(1996-1999) [21/21] 王全正(1996-2003) [4/4] 莊聲宏(1997-2004) [11/11] 詹宗晃(2000-2008) [2/2] 賴基銘(2004-2008) [41/47] 阮麗蓉(2000-2006) [6/7] 陳俊叡(2003-2007) [6/6] 馬彥英(1997-1999) [1/1] 黃奇英(2005-2007) [9/10] Siblings 分子與基因醫學研究所 [924/967] 生技與藥物研究所 [833/1011] 生醫工程與奈米醫學研究所 [1221/1341] 免疫醫學研究中心 [226/238] 神經及精神醫學研究中心 [787/809] 細胞及系統醫學研究所 [758/818] 感染症與疫苗研究所 [1544/1621] 群體健康科學研究所 [2881/3011] 國家環境醫學研究所 [1563/1594] 國家蚊媒傳染病防治研究中心 [103/105] 高齡醫學暨健康福祉研究中心 [223/231] 論壇 [2/2] 生醫資源中心 [7/7] 研究生培育合作學程 [191/194] 核心儀器設施中心 [9/9] 病理核心實驗室 [14/14] 實驗動物中心 [9/9] 行政管理部門 [18/18] Community Statistics 近3年內發表的文件:338(14.01%) 含全文筆數:2253(93.41%) 文件下載次數統計 下載大於0次:2253(100.00%) 下載大於100次:2253(100.00%) 檔案下載總次數:1618941(28.86%) 最後更新時間: 2024-12-05 05:40 Top Upload Loading... Top Download Loading... Recent Submissions Gastrointestinal comorbidities in p... Polygenic risk score and lung adeno... Cooperative participation of CagA a... Pathological response following neo... Registry of genetic alterations of ... Activated single nucleotide mismatc... Taiwan nationwide study of first-li... The effectiveness of virtual passpo... Special Issue "Bioinformatics ... Evaluating a natural language proce...

Jump to a point in the index: (Choose year) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (Choose month) January February March April May June July August September October November December Or type in a year:

Ordering With Most Recent First Show Oldest First

Showing items 751-760 of 2412. (242 Page(s) Totally) << < 71 72 73 74 75 76 77 78 79 80 > >> View [10|25|50] records per page

Date	Title	Relation
2018-10-23	Fecal microbiota transplantation confers beneficial metabolic effects of diet and exercise on diet-induced obese mice	Scientific Reports. 2018 Oct 23;8:Article number 15625.
2018-10-11	Tinospora cordifolia extract prevents cadmium-induced oxidative stress and hepatotoxicity in experimental rats	Journal of Ayurveda and Integrative Medicine. 2018 Oct-Dec;9(4):252-257.
2018-10-08	Opposite regulation of CHOP and GRP78 and synergistic apoptosis induction by selenium yeast and fish Oil via AMPK activation in lung adenocarcinoma cells	Nutrients. 2018 Oct 8;10(10):Article number 1458.
2018-10-01	Protein phosphatase 2A as therapeutic targets in various disease models	Life Sciences. 2018 Oct 1;210:40-46.
2018-10	Inflammatory response and PM2.5 exposure of urban traffic conductors	Aerosol and Air Quality Research. 2018 Oct;18(10):2633-2642.
2018-10	Identification of novel Cdc7 kinase inhibitors as anti-cancer agents that target the interaction with Dbf4 by the fragment complementation and drug repositioning approach	EBioMedicine. 2018 Oct;36:241-251.
2018-10	Multicenter, phase II trial of biweekly S-1, leucovorin (LV), oxaliplatin and gemcitabine (SLOG) in metastatic pancreatic adenocarcinoma (mPDAC): Final report of TCOG T1211 study	Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 736P.
2018-10	NAPOLI-1 phase III trial outcomes by prior surgery, and disease stage, in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)	Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 733P.
2018-10	The prognostic value of the modified glasgow prognostic score (mGPS) in predicting overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV)	Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 749P.
2018-10	Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1	Annals of Oncology. 2018 Oct;29(Suppl. 8):250-251.

Showing items 751-760 of 2412. (242 Page(s) Totally) << < 71 72 73 74 75 76 77 78 79 80 > >> View [10|25|50] records per page